Navigation Links
Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting

cluded a physical examination and vital signs at each study visit, ECG, laboratory tests, and tests of drug plasma concentration in addition to adverse event monitoring.

Key inclusion criteria for the study included the ability to complete the Timed 25 Foot Walk twice at screening with times averaging between 8 and 45 seconds, having a confirmed diagnosis of MS and having a stable condition. Key exclusion criteria included a history of seizures, having previous treatment with fampridine or having an MS exacerbation within 60 days of screening.

About MS

Multiple sclerosis is a chronic, usually progressive disease of the central nervous system in which the immune system attacks and destroys the structure, and therefore degrades the function, of nerve cells. Approximately 400,000 Americans have MS, and every week about 200 people are newly diagnosed. Most are between the ages of 20 and 50, and women are affected two to three times as much as men. Worldwide, MS may affect 2.5 million individuals.

Over time, MS tends to lead to increasing disabilities such as walking impairment, muscle weakness, problems with cognition, speech or vision impairments. Approximately 80 percent of people with MS experience some form of walking disability. Within 15 years of an MS diagnosis, 50 percent of patients often require assistance walking and in later stages, about a third of patients are unable to walk. These complications may make it harder for people to work and may interfere with their ability to perform common, daily activities.

According to the National Multiple Sclerosis Society (NMSS), the direct costs of medical care for MS patients in the United States exceed $6 billion annually. Additionally, a recent NMSS analysis estimated the total cost of MS, including medical and non-medical care, production losses, and informal care, at more than $47,000 per U.S. patient per year.

About Fampridine-SR

Fampridine-SR is a sustained-release
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Acorda Therapeutics Presents Fampridine-SR Data at ACTRIMS Meeting
2. Acorda Therapeutics to Host Analyst and Investor Reception
3. Acorda Therapeutics Presentation of Fampridine-SR Phase 3 Data Selected for Scientific Highlights Program at the American Academy of Neurology Meeting
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
6. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
7. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
8. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
9. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
10. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
11. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
Post Your Comments:
(Date:7/31/2014)... (NYSE: RMD ) today announced results for its ... 2014.  Revenue for the quarter was $415.2 million, flat compared ... decrease on a constant currency basis). Net income was $87.7 ... ended June 30, 2013. Diluted earnings per share for the ... the quarter ended June 30, 2013.  The ...
(Date:7/31/2014)... (the "Company") (Nasdaq: PCYC ) today reported financial ... 2014. Financial Results for the Six Months and ... the quarter ended June 30, 2014 increased to $113.0 million ... primarily due to IMBRUVICA ® (ibrutinib) net product revenue ... six months ended June 30, 2014 increased to $232.4 million ...
(Date:7/31/2014)... MOUNTAIN VIEW, Calif. , July 31, 2014 ... ) today provided an update on its pipeline ... of 2014, Alexza expects to initiate a Phase ... which is being developed for the management of ... identified two new Staccato -based product candidates ...
Breaking Medicine Technology:RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 3RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 4RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 5RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 6RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 7RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 8RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 9RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 10RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 11RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 12RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 13Pharmacyclics Reports Second Quarter 2014 Results 2Pharmacyclics Reports Second Quarter 2014 Results 3Pharmacyclics Reports Second Quarter 2014 Results 4Pharmacyclics Reports Second Quarter 2014 Results 5Pharmacyclics Reports Second Quarter 2014 Results 6Pharmacyclics Reports Second Quarter 2014 Results 7Pharmacyclics Reports Second Quarter 2014 Results 8Pharmacyclics Reports Second Quarter 2014 Results 9Pharmacyclics Reports Second Quarter 2014 Results 10Pharmacyclics Reports Second Quarter 2014 Results 11Pharmacyclics Reports Second Quarter 2014 Results 12Pharmacyclics Reports Second Quarter 2014 Results 13Pharmacyclics Reports Second Quarter 2014 Results 14Pharmacyclics Reports Second Quarter 2014 Results 15Pharmacyclics Reports Second Quarter 2014 Results 16Pharmacyclics Reports Second Quarter 2014 Results 17Pharmacyclics Reports Second Quarter 2014 Results 18Pharmacyclics Reports Second Quarter 2014 Results 19Pharmacyclics Reports Second Quarter 2014 Results 20Pharmacyclics Reports Second Quarter 2014 Results 21Pharmacyclics Reports Second Quarter 2014 Results 22Pharmacyclics Reports Second Quarter 2014 Results 23Pharmacyclics Reports Second Quarter 2014 Results 24
... Feb. 14, 2011 OXIS International, Inc., (OTC Bulletin ... that Anthony Cataldo, Chief Executive Officer, and Bernie Landes, ... Lippert/Heilshorn & Associates Life Sciences & Medical Technologies On-Line ... Eastern (9:30 a.m. Pacific). A webcast of ...
... ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX ... definitive agreement to acquire SynthRx, Inc. (SynthRx), a private ... and antithrombotic agent, poloxamer 188 (188). ... for ADVENTRX, adding another late-stage asset to our pipeline," ...
Cached Medicine Technology:ADVENTRX Signs Definitive Agreement to Acquire SynthRx Inc. 2ADVENTRX Signs Definitive Agreement to Acquire SynthRx Inc. 3ADVENTRX Signs Definitive Agreement to Acquire SynthRx Inc. 4ADVENTRX Signs Definitive Agreement to Acquire SynthRx Inc. 5ADVENTRX Signs Definitive Agreement to Acquire SynthRx Inc. 6
(Date:8/1/2014)... 2014 Parker Waichman LLP, a national ... injured by defective medical devices and drugs reports that ... Ethicon surgical power morcellator devices used for the removal ... the spread of cancer associated with power morcellators, according ... 2014. , Johnson & Johnson had previously ceased ...
(Date:8/1/2014)... Aug. 1, 2014 (HealthDay News) -- Almost 140 ... school transportation in the United States. But ... bus-related catastrophes, Dawne Gardner, injury prevention coordinator at ... Center, said in a medical center news release. ... returning to school, it,s important for parents and ...
(Date:8/1/2014)... The evolving healthcare landscape presents ... At ThoughtSpot 2014, AmerisourceBergen and Good Neighbor Pharmacy’s ... resources to enhance patient care and profitability. At ... issues to give independent pharmacists the tools they ... ThoughtSpot show attendance experienced a nearly 70% increase ...
(Date:8/1/2014)... DC (PRWEB) August 01, 2014 ... Thompson (D-CA), Gregg Harper (R-MS), and Peter Welch ... 5380, the Medicare Telehealth Parity Act of 2014, ... fully support this effort to improve healthcare access ... chief executive officer of ATA. "These cost-saving provisions ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 On Monday, ... California NextGen User Symposium in San Francisco, CA. Now ... at the JW Marriott Union Square hotel. , “We ... get up to speed with ACA compliance issues,” Quirk ... month. The symposium provides attendees guidance with NextGen implementation ...
Breaking Medicine News(10 mins):Health News:J&J's Ethicon Unit Recalls its Power Morcellator Devices After Warnings by Federal Regulators and Concern About Risk of Spreading Occult Cancer, Parker Waichman Comments 2Health News:J&J's Ethicon Unit Recalls its Power Morcellator Devices After Warnings by Federal Regulators and Concern About Risk of Spreading Occult Cancer, Parker Waichman Comments 3Health News:J&J's Ethicon Unit Recalls its Power Morcellator Devices After Warnings by Federal Regulators and Concern About Risk of Spreading Occult Cancer, Parker Waichman Comments 4Health News:Expert Offers School Bus Safety Tips 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 3Health News:ThoughtSpot 2014 Inspires as General Session Concludes 4Health News:ThoughtSpot 2014 Inspires as General Session Concludes 5Health News:ATA Applauds Bill on Medicare Telemedicine Improvements 2Health News:Quirk Healthcare Foundation Hosts Fifth Annual California NextGen User Symposium and Launches First Annual Florida NextGen User Symposium 2
... Little League Baseball World Series, CHICAGO, Aug. ... announced the winner of its annual slogan contest ... their coaches and parents,about tobacco addiction and the ... smokeless tobacco. This year,s slogan contest winner is,Joe ...
... The Association of,International Automobile Manufacturers (AIAM) announced ... the Children,s Hospital,of Philadelphia (CHOP) that will provide ... involved in automobile crashes. For more than a ... scientific foundation for new,product development, improved federal motor ...
... http://www.TCSHealthcare.com , AUBURN, Calif., Aug. 20 ... trends in how health care professionals are ... care management,interventions. The survey results highlight the ... functionality, standardization and,interoperability to optimize clinical and ...
... CREEK, Calif., Aug. 20 Longs Drug,Stores Corporation ... from,continuing operations for the second quarter ended July ... share, including $0.7 million of after-tax,charges, or $0.02 ... and asset impairments and legal reserves, a 6.8 ...
... illegally sell alcohol, study finds , , WEDNESDAY, Aug. 20 (HealthDay ... vendors in American sports stadiums will still gladly sell you ... from a new study that suggests stadiums aren,t doing enough ... People who clearly appeared underage were able to buy alcohol ...
... Care as State Approves Only,Program in The Bronx, ... liver disease and need a liver transplant will no ... important follow-up,care outside the borough of the Bronx. Area ... care locally, without having to travel,long distances, as a ...
Cached Medicine News:Health News:Slogan Contest Educates Young Baseball Players About the Dangers of Tobacco Use 2Health News:AIAM Sponsors Leading Child Safety Research Initiative 2Health News:New Health IT Survey for Care Management Services Shows Opportunities for Integration, Standardization and Innovation 2Health News:New Health IT Survey for Care Management Services Shows Opportunities for Integration, Standardization and Innovation 3Health News:Longs Drug Stores Corporation Reports Second Quarter Results 2Health News:Longs Drug Stores Corporation Reports Second Quarter Results 3Health News:Longs Drug Stores Corporation Reports Second Quarter Results 4Health News:Longs Drug Stores Corporation Reports Second Quarter Results 5Health News:Longs Drug Stores Corporation Reports Second Quarter Results 6Health News:Longs Drug Stores Corporation Reports Second Quarter Results 7Health News:Longs Drug Stores Corporation Reports Second Quarter Results 8Health News:Longs Drug Stores Corporation Reports Second Quarter Results 9Health News:Longs Drug Stores Corporation Reports Second Quarter Results 10Health News:Longs Drug Stores Corporation Reports Second Quarter Results 11Health News:Longs Drug Stores Corporation Reports Second Quarter Results 12Health News:Longs Drug Stores Corporation Reports Second Quarter Results 13Health News:Underaged, Inebriated Easily Get Drinks at Stadiums 2Health News:Liver Transplant Program Established At Montefiore 2Health News:Liver Transplant Program Established At Montefiore 3Health News:Liver Transplant Program Established At Montefiore 4
... This remarkable anti-reflux valve ... plastic housing which prevents the ... closed when in sitting or ... virtually self-cleaning and interference free ...
... valve is enclosed in a ... the valve from being accidentally ... or reclining positions. The valve ... free ensuring uninterrupted flow and ...
... The VerifyNow (Ultegra) System is ... which measures platelet induced aggregation as ... system consists of an instrument, a ... assay device contains reagents based on ...
The Multiple Perfusion set provides simultaneous perfusion of the aortic root and up to three or more vein grafts. The set features an inlet port with female luer and clamp attached to an adapter whi...
Medicine Products: